PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Donepezil in the Prevention of Post-Operative Cognitive Decline
Phase 4
Completed
- Conditions
- Postoperative ComplicationsDelirium
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2008-03-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT00182845
- Locations
- 🇺🇸
University Hospital, Clarian Health Partners, Indianapolis, Indiana, United States
Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson's Disease.
Phase 4
Terminated
- Conditions
- Parkinson Disease
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2007-05-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 220
- Registration Number
- NCT00174239
- Locations
- 🇪🇸
Pfizer Investigational Site, Sevilla, Spain
Vaspect Study - An Open-Label Trial Of Donepezil in Vascular and Mixed Dementia
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 149
- Registration Number
- NCT00174382
- Locations
- 🇨🇦
Pfizer Investigational Site, Regina, Saskatchewan, Canada
Prevention of Growth Retardation by Early Treatment With Growth Hormone (GH) in Children With CJA Treated by Corticosteroid Therapy
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-12-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 21
- Registration Number
- NCT00174291
- Locations
- 🇫🇷
Pfizer Investigational Site, Paris, France
Treatment With Recombinant Human Growth Hormone (GH) in Children With Short Stature Secondary to a Long Term Corticoid Therapy
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-12-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT00174187
- Locations
- 🇫🇷
Pfizer Investigational Site, Paris, France
A Study to Investigate the Pharmacokinetics, Safety and Tolerability of Voriconazole in Children
Phase 1
Completed
- Conditions
- Neutropenia
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-05-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 49
- Registration Number
- NCT00174473
Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients
Phase 2
Completed
- Conditions
- Breast Neoplasms
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-04-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 46
- Registration Number
- NCT00174343
- Locations
- 🇫🇷
Pfizer Investigational Site, St. Cloud, France
Assessment Of Duration Of Action, Safety & Toleration Of UK369,003 and Cialis In Patients With Erectile Dysfunction
Phase 2
Completed
- Conditions
- Impotence
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2006-07-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 300
- Registration Number
- NCT00174486
MEK Inhibitor PD-325901 To Treat Advanced Non-Small Cell Lung Cancer
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2009-03-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 34
- Registration Number
- NCT00174369
- Locations
- 🇺🇸
Pfizer Investigational Site, Philadelphia, Pennsylvania, United States
Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2009-01-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 22
- Registration Number
- NCT00174434
- Locations
- 🇺🇸
Pfizer Investigational Site, New York, New York, United States
© Copyright 2025. All Rights Reserved by MedPath